Primary care physician

PCP Use of Clover Assistant Correlated with Increased Medication Fills for Patients who Were Previously Non-Adherent

Retrieved on: 
Monday, January 8, 2024

FRANKLIN, Tenn., Jan. 08, 2024 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (NASDAQ: CLOV) (“Clover,” “Clover Health” or the “Company”), a physician enablement company committed to bringing access to great healthcare to everyone on Medicare, today released research demonstrating Clover Assistant’s impact on medication adherence.

Key Points: 
  • FRANKLIN, Tenn., Jan. 08, 2024 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (NASDAQ: CLOV) (“Clover,” “Clover Health” or the “Company”), a physician enablement company committed to bringing access to great healthcare to everyone on Medicare, today released research demonstrating Clover Assistant’s impact on medication adherence.
  • The paper, Clover Assistant Use and Medication Adherence for Common Chronic Conditions , examines the correlation between Primary Care Physician (PCP) use of Clover Assistant and levels of adherence to prescribed medications for common chronic conditions including diabetes, high blood pressure, and high cholesterol.
  • The lead author of the study, Dr. Kumar Dharmarajan, Chief Medical Officer of Clover Assistant, Adjunct Professor at Yale, and practicing cardiologist said, “Clinicians have no idea if patients pick up their prescribed medications at the pharmacy.
  • To learn more about Clover Assistant visit: www.cloverassistant.com

Responsible AI Institute Forms Inaugural Responsible Generative AI Consortium and Launches First in Series of Industry-Specific Testbeds to Operationalize AI Safety, Build Workforce Capacity

Retrieved on: 
Wednesday, June 28, 2023

Learnings from the Consortium will be unveiled at today’s Symposium on Responsible Generative AI in Healthcare hosted at St Edmund’s College, University of Cambridge.

Key Points: 
  • Learnings from the Consortium will be unveiled at today’s Symposium on Responsible Generative AI in Healthcare hosted at St Edmund’s College, University of Cambridge.
  • It will also facilitate cutting-edge research, sharing of case studies and executive education programs in responsible adoption of generative AI.
  • Policymakers can manage generative AI and its surrounding policies more efficiently to ensure the protection of consumers and promote the responsible use of AI.
  • We’ve joined forces with RAI Institute to be a part of the first-ever Responsible AI Consortium and look forward to ushering in a new era of responsible generative AI across industries worldwide,” said Seth Dobrin, CEO at Trustwise.

Innosphere Ventures, Colorado BioScience Association, and Colorado BioScience Institute Announce the Colorado Life Sciences Incubation Program 2023 Cohort

Retrieved on: 
Wednesday, April 26, 2023

Denver and Fort Collins, Colo., April 26, 2023 (GLOBE NEWSWIRE) -- Innosphere Ventures , Colorado BioScience Association (CBSA), and Colorado BioScience Institute (The Institute) announce the eight startup and scaleup companies that were selected to join the 2023 Colorado Life Sciences Incubation Program.

Key Points: 
  • Denver and Fort Collins, Colo., April 26, 2023 (GLOBE NEWSWIRE) -- Innosphere Ventures , Colorado BioScience Association (CBSA), and Colorado BioScience Institute (The Institute) announce the eight startup and scaleup companies that were selected to join the 2023 Colorado Life Sciences Incubation Program.
  • With funding support from the state of Colorado, the Colorado Life Sciences Incubation Program  provides life sciences startups with a powerful advantage by leveraging the combined expertise and insights of three leading organizations from the state’s life sciences and innovation ecosystem.
  • We remain committed to nurturing and supporting innovative life sciences startups through our unique incubation program, which combines the expertise and resources of Innosphere Ventures, the Colorado Bioscience Association, and the Colorado Bioscience Institute.
  • “Colorado BioScience Association and Colorado BioScience Institute extend a warm welcome to the promising start ups selected for this year’s Colorado Life Sciences Incubation Program cohort,” said Elyse Blazevich, President and CEO of Colorado BioScience Association and President of Colorado BioScience Institute.

Penn Highlands Healthcare Shares the ABCs of RSV

Retrieved on: 
Monday, November 28, 2022

In very young infants with RSV, the only symptoms may be irritability, decreased activity and breathing difficulties.

Key Points: 
  • In very young infants with RSV, the only symptoms may be irritability, decreased activity and breathing difficulties.
  • Almost all children will have had an RSV infection by their second birthday, said Dr. Sisk.
  • According to the Centers for Disease Control and Prevention, healthy adults and infants infected with RSV do not usually need to be hospitalized.
  • Whether you need an appointment for a sick child, an immunization or an annual physical, the Primary Care Physicians at Penn Highlands Family Medicine can take care of your whole family.

The International Consortium for Health Outcomes Measurement (ICHOM) will hold the largest gathering of value-based health care leaders in the world on 1-3 November 2022

Retrieved on: 
Wednesday, June 29, 2022

Hundreds of healthcare stakeholders are expected to attend inperson, including providers, industry, life sciences, academia and patient representatives.

Key Points: 
  • Hundreds of healthcare stakeholders are expected to attend inperson, including providers, industry, life sciences, academia and patient representatives.
  • The programme will take place over three days with two key themes: Future Healthcare Systems and Healthcare Transformation Drivers.
  • There will be plenty of networking opportunities including an ICHOM welcome drinks reception, networking breakfasts and interactive conference sessions.
  • Is equitable and inclusive care possible without standardized outcomes measurement?

The International Consortium for Health Outcomes Measurement (ICHOM) will hold the largest gathering of value-based health care leaders in the world on 1-3 November 2022

Retrieved on: 
Wednesday, June 29, 2022

Hundreds of healthcare stakeholders are expected to attend inperson, including providers, industry, life sciences, academia and patient representatives.

Key Points: 
  • Hundreds of healthcare stakeholders are expected to attend inperson, including providers, industry, life sciences, academia and patient representatives.
  • The programme will take place over three days with two key themes: Future Healthcare Systems and Healthcare Transformation Drivers.
  • There will be plenty of networking opportunities including an ICHOM welcome drinks reception, networking breakfasts and interactive conference sessions.
  • Is equitable and inclusive care possible without standardized outcomes measurement?

LumiraDx COVID-19 & Flu A/B Rapid Antigen Test Achieves CE Marking

Retrieved on: 
Thursday, December 23, 2021

LONDON, Dec. 23, 2021 /PRNewswire/ --LumiraDx (Nasdaq: LMDX), a next-generation point of care diagnostics company, today announced its SARS-CoV-2& Flu A/BAntigen Test has achieved CE Marking.

Key Points: 
  • LONDON, Dec. 23, 2021 /PRNewswire/ --LumiraDx (Nasdaq: LMDX), a next-generation point of care diagnostics company, today announced its SARS-CoV-2& Flu A/BAntigen Test has achieved CE Marking.
  • Existing respiratory tests on the LumiraDx Platform include the company's SARS-CoV-2 Antigen, SARS-CoV-2 Antibody and SARS-CoV-2 Antigen Pool tests which achieved CE Marking in August 2020, September 2020 and March 2021, respectively.
  • Shipments of the LumiraDx SARS-CoV-2 & Flu A/B Antigen Test will begin shortly.
  • Private Securities Litigation Reform Act of 1995, including statements regarding the performance and benefits of the SARS-CoV-2 & Flu A/B Antigen Test.

LumiraDx COVID-19 & Flu A/B Rapid Antigen Test Achieves CE Marking

Retrieved on: 
Thursday, December 23, 2021

LONDON, Dec. 23, 2021 /PRNewswire/ -- LumiraDx (Nasdaq: LMDX), a next-generation point of care diagnostics company, today announced its SARS-CoV-2 & Flu A/B Antigen Test has achieved CE Marking. The microfluidic immunofluorescence assay can quickly verify potential infection for patients suspected of influenza and/or COVID-19, helping to identify and differentiate the underlying cause of respiratory illness and to inform treatment decisions at the point of care. Existing respiratory tests on the LumiraDx Platform include the company's SARS-CoV-2 Antigen, SARS-CoV-2 Antibody and SARS-CoV-2 Antigen Pool tests which achieved CE Marking in August 2020, September 2020 and March 2021, respectively. 

Key Points: 
  • Existing respiratory tests on the LumiraDx Platform include the company's SARS-CoV-2 Antigen, SARS-CoV-2 Antibody and SARS-CoV-2 Antigen Pool tests which achieved CE Marking in August 2020, September 2020 and March 2021, respectively.
  • Shipments of the LumiraDx SARS-CoV-2 & Flu A/B Antigen Test will begin shortly.
  • The SARS-CoV-2& Flu A/B Antigen Test helps distinguish between the viral respiratory infections SARS-CoV-2 and influenza while also differentiating between influenza A and influenza B.
  • Private Securities Litigation Reform Act of 1995, including statements regarding the performance and benefits of the SARS-CoV-2 & Flu A/B Antigen Test.

agilon health to Report Second Quarter 2021 Financial Results

Retrieved on: 
Tuesday, July 13, 2021

agilon health, inc. (NYSE: AGL), the company transforming health care for seniors by empowering primary-care physicians to focus on the entire health of their patients, announced that it will release its financial results for the second quarter 2021 after the market closes on Wednesday, August 4, 2021, and host a conference call at 8:30 AM Eastern Time on Thursday, August 5, 2021 to discuss the results.

Key Points: 
  • agilon health, inc. (NYSE: AGL), the company transforming health care for seniors by empowering primary-care physicians to focus on the entire health of their patients, announced that it will release its financial results for the second quarter 2021 after the market closes on Wednesday, August 4, 2021, and host a conference call at 8:30 AM Eastern Time on Thursday, August 5, 2021 to discuss the results.
  • A replay of the call will be available via webcast for on-demand listening shortly after the completion of the call.
  • agilon health is transforming health care for seniors by empowering primary-care physicians to focus on the entire health of their patients.
  • With rapidly growing appeal, agilon is scaled to grow and is here to help our nations best independent physician groups have a sustained, thriving future.

agilon health Names Karen McLoughlin to its Board of Directors

Retrieved on: 
Monday, July 12, 2021

agilon health, inc. (NYSE: AGL), the company transforming health care for seniors by empowering primary-care physicians to focus on the entire health of their patients, has named Karen McLoughlin to its board of directors.

Key Points: 
  • agilon health, inc. (NYSE: AGL), the company transforming health care for seniors by empowering primary-care physicians to focus on the entire health of their patients, has named Karen McLoughlin to its board of directors.
  • Karens deep expertise across financial operations, digital transformation and strategy will be an invaluable resource to agilon health, said Ron Williams, board chairman.
  • We are delighted to welcome Karen to agilons board.
  • agilon health is transforming health care for seniors by empowering primary-care physicians to focus on the entire health of their patients.